NVP-BGT226 - PI3K/mTOR Dual Inhibitor. CAS# 1245537-68-1 ral-LSB Approximately one third of patients

Approximately one third of patients with HCC whose tumors express FGF19 together with FGFR4 and its coreceptor klotho β (KLB) could potentially respond to treatment with an FGFR4 inhibitor

in a canine model of coronary artery thrombosis

InChi: InChI=1S/C23H28N2O2

Gorasiya S

29)24-9-10-25(22(15-24)17-27)31-18-21-11-13-30-14-12-21/h5-10

NVP-BGT226 - PI3K/mTOR Dual Inhibitor. CAS# 1245537-68-1 ral-LSB Approximately one third of patientsNVP BGT226, CAS No. 1245537 68 1, is a novel dual PI3K mTOR inhibitor with an IC50 ~1 nM. In cellular assays it could produce nearly complete inhibition of PI3K signaling at low nanomolar (<50 nM) concentrations. Flow cytometric analysis revealed an accumulation of cells in the G0G1 phase with a concomitant loss in the S phase. TUNEL assay and the analysis of Caspase 3 7 and PARP indicated that BGT226 induced cancer cell death through an apoptosis